Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Qiagen ( (QGEN) ) just unveiled an update.
The Netherlands Authority for the Financial Markets (AFM) has informed Qiagen N.V. of a new substantial shareholding notification relating to the company. According to the AFM register, DWS Investment GmbH holds 2,244,810 ordinary shares in Qiagen, corresponding to a capital interest of 1.09% and voting rights of 2.76%, held indirectly.
The disclosure highlights a notable institutional investor position in Qiagen, underscoring continued interest from asset managers in the company’s equity. Qiagen emphasized that it is not responsible for the accuracy of the AFM notification, which is based on information published in the regulator’s official register.
The most recent analyst rating on (QGEN) stock is a Buy with a $58.00 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.
More about Qiagen
Qiagen N.V., based in Venlo, Netherlands, operates in the life sciences and molecular diagnostics industry, with its shares listed on multiple European exchanges as well as the NYSE and Swiss markets. The company attracts a broad international investor base, with its stock registered under ISIN NL0015002SN0 and traded across major regulated and free markets.
Average Trading Volume: 2,103,103
Technical Sentiment Signal: Strong Buy
Current Market Cap: $10.03B
For detailed information about QGEN stock, go to TipRanks’ Stock Analysis page.